Eli Lilly and Company — Foundayo (orforglipron) - (ATTAIN-1) · Obesity.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (10/15/25) through T+5. Run-up high $1109.94 on 12/2/25, low $799.57 on 10/28/25 (T-120 to T-1). FDA decision 4/1/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-04-01
OutcomeApproved
Drug / candidateFoundayo (orforglipron) - (ATTAIN-1)